RFP: Measles Rapid Diagnostic Test Deployment Pilot StudyDownload

Gavi The Vaccine Alliance is seeking a firm that will provide support in improving availability and use of fit-for-purpose measles IgM Rapid Diagnostic Tests (RDTs). Such measles IgM RDTs are expected to be available by the 1st quarter of 2024. Efforts to improve access to and use of measles IgM RDTs will be aided by measures including pooling procurement across low- and middle-income countries eligible for Gavi funding support and supporting the development of guidance on how to best deploy such tests to guide immunization programme decision making.